Supernus announces FDA approval of sNDA to expand Oxtellar XR® label
Supernus announced the FDA has approved the Company’s sNDA for Oxtellar XR®. The application requested FDA approval to expand the indication for Oxtellar XR® beyond the current indication of adjunctive therapy in the treatment of partial-onset seizures in adults and in children 6 to 17 years of age. December 14, 2018